Immuno-oncological Efficacy of RXDX-106, a Novel TAM (TYRO3, AXL, MER) Family Small-Molecule Kinase Inhibitor.
Yokoyama Y, Lew ED, Seelige R, Tindall EA, Walsh C, Fagan PC, Lee JY, Nevarez R, Oh J, Tucker KD, Chen M, Diliberto A, Vaaler H, Smith KM, Albert A, Li G, Bui JD.
Yokoyama Y, et al. Among authors: seelige r.
Cancer Res. 2019 Apr 15;79(8):1996-2008. doi: 10.1158/0008-5472.CAN-18-2022. Epub 2019 Feb 5.
Cancer Res. 2019.
PMID: 30723115